Overview

High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)

Status:
Active, not recruiting
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
Novel therapies are desperately needed for treatment of COVID-19 patients. At present, there are no proven interventions to prevent progression of the disease or to rapidly treat patients with COVID-19 related respiratory failure. Data on the original coronavirus -SARS pneumonia suggested that high dose (>160ppm) inhaled Nitric Oxide could have beneficial effects also on COVID-19, due to the genomic similarities between these two coronaviruses (1-3). This study will test whether high dose inhaled nitric oxide is safe and can reverse virus burden and respiratory failure in patients on mechanical ventilation.
Phase:
Phase 1
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Nitric Oxide